REPLY TO: OFF-LABEL USE OF REPURPOSED IVERMECTIN FOR SARS-COV-2 INFECTION SHOULD BE BANNED BY AUTHORITIES UNLESS EFFICACY IS PROVEN
- Author:
Aina Amanina Abdul Jalil
1
;
Filza Nur Athirah Tar’ali
1
Author Information
- Publication Type:Letter
- Keywords: Attitude; COVID-19; Ivermectin; Knowledge; Prevalence
- From:Malaysian Family Physician 2024;19(1):1-3
- CountryMalaysia
- Language:English
- Abstract: REPLY TO: OFF-LABEL USE OF REPURPOSED IVERMECTIN FOR SARS-COV-2 INFECTION SHOULD BE BANNED BY AUTHORITIES UNLESS EFFICACY IS PROVEN: ank you for the opportunity to address the concerns raised regarding our recent publication titled ‘Knowledge, attitude and prevalence of ivermectin use as coronavirus disease treatment: A cross-sectional study among a Malaysian population’.1,2 We appreciate the critical evaluation of our study design. Indeed, while electronic questionnaires o er convenience, we acknowledge their limitations, including the potential for inaccurate reporting and di culty in con rming the identity of respondents. However, they also o er advantages such as ease of data collection and the potential for anonymity, which can encourage more candid responses. While electronic surveys have inherent limitations, they are coste ective and facilitate easy data collection, particularly during the COVID-19 pandemic, when the data were collected and when in-person interactions were limited. Rigorous validation processes can help ensure the reliability of collected data. We agree that future research could bene t from a more robust methodology, such as employing a multicentre design to enhance the representativeness of the sample.
- Full text:2026102022072980731Reply to Off-label use of.pdf
